An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, single-center, dose-escalation study in patients with
advanced solid tumors. Six dose levels (100, 200, 400, 600, 800, and 1000 mg/day) are planned
for the study. In this study, OPB-31121's potential for toxic effects will be evaluated in
patients with advanced solid tumors to evaluate the recommended dose for use in subsequent
studies. The pharmacokinetics and antitumor effect of the compound will also be investigated.